Winn Feline Foundation: Treatment of Feline Hyperthyroidism with Carbimazole
Treatment of Feline Hyperthyroidism with Carbimazole
Frenais, R., et al., Clinical efficacy and safety of a once-daily formulation of carbimazole in cats with hyperthyroidism. J Small Anim Pract, 2009. 50(10): p. 510-5.
Traditionally, medical treatment of feline hyperthyroidism has involved daily use of the azole drugs, methimazole or its pro-drug, carbimazole. Many cats require twice daily treatment with these drugs. A novel controlled-release formulation of carbimazole (Vidalta) has been developed by Intervet. These researchers evaluated the efficacy and safety of this new carbimazole formulation via a multi-center study of 44 client-owned cats with hyperthyroidism. Treatment was started at 15 mg/cat once daily, and dose was adjusted as required. Cats were followed for 53 weeks. The median dose over the study period was 10-15 mg/cat once daily. Clinical signs improved in almost all cats within 3 weeks after treatment was started. An increase in blood urea nitrogen (BUN) was noted in 25% of the cats, eosinophilia was noted in 20%, and lymphopenia in 16%. The researchers conclude that once daily administration of controlled-release carbimazole is effective with acceptable tolerance during short and long term treatment of feline hyperthyroidism. [SL]
>> PubMed Abstract
Related articles:
Frenais, R., S. Burgaud, and L.J.I. Horspool, Pharmacokinetics of controlled-release carbimazole tablets support once daily dosing in cats. Journal of Veterinary Pharmacology and Therapeutics, 2008. 31(3): p. 213-219.
>> PubMed Abstract
Trepanier, L.A., Medical management of hyperthyroidism. Clin Tech Small Anim Pract, 2006. 21(1): p. 22-8.
>> PubMed Abstract
More on cat health: Winn Feline Foundation Library
Join us on Facebook
Follow us on TwitterProviding expert cat health information and supporting cat health research since 1968.
Traditionally, medical treatment of feline hyperthyroidism has involved daily use of the azole drugs, methimazole or its pro-drug, carbimazole. Many cats require twice daily treatment with these drugs. A novel controlled-release formulation of carbimazole (Vidalta) has been developed by Intervet. These researchers evaluated the efficacy and safety of this new carbimazole formulation via a multi-center study of 44 client-owned cats with hyperthyroidism. Treatment was started at 15 mg/cat once daily, and dose was adjusted as required. Cats were followed for 53 weeks. The median dose over the study period was 10-15 mg/cat once daily. Clinical signs improved in almost all cats within 3 weeks after treatment was started. An increase in blood urea nitrogen (BUN) was noted in 25% of the cats, eosinophilia was noted in 20%, and lymphopenia in 16%. The researchers conclude that once daily administration of controlled-release carbimazole is effective with acceptable tolerance during short and long term treatment of feline hyperthyroidism. [SL]
>> PubMed Abstract
Related articles:
Frenais, R., S. Burgaud, and L.J.I. Horspool, Pharmacokinetics of controlled-release carbimazole tablets support once daily dosing in cats. Journal of Veterinary Pharmacology and Therapeutics, 2008. 31(3): p. 213-219.
>> PubMed Abstract
Trepanier, L.A., Medical management of hyperthyroidism. Clin Tech Small Anim Pract, 2006. 21(1): p. 22-8.
>> PubMed Abstract
More on cat health: Winn Feline Foundation Library
Join us on Facebook
Follow us on TwitterProviding expert cat health information and supporting cat health research since 1968.